Immunometabolism company Sitryx expands into new space at TOSP: Second occupier for Bellhouse Building at The Oxford Science Park Oxford, UK.
Sitryx, a company which is focused on regulating cell metabolism to develop disease-modifying therapeutics in inflammatory diseases and immuno-oncology, announces that it has expanded into new premises in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK's leading parks for science and technology companies. Sitryx has developed rapidly since its transformative 2020 licensing and research collaboration with pharmaceutical company Eli Lilly. Its new premises provide the ideal environment for growth as its immunometabolism work progresses. Relocating from the Sherrington Building at TOSP, Sitryx is the second occupier of the new Bellhouse Building.
Currently employing 23 staff, of which 16 are research scientists, Sitryx has moved into 5,500 sq ft of purpose-built laboratory and office space. This provides a high-quality lab environment supporting an expanding research team, and a cohesive collaboration environment, supporting all aspects of the company's activities.
In order to inspire science and technology occupiers, and in recognition of his achievements, the Bellhouse building was named after the academic entrepreneur Professor Brian Bellhouse. He read Mathematics at Magdalen College Oxford, which owns TOSP, and become a Professor of Engineering Science. Professor Bellhouse was one of the University's earliest entrepreneurs, forming PowderJect in 1993 and locating it at The Oxford Science Park.
Rory Maw, Bursar of Magdalen College & Director of TOSP, said, 'Fast growing and innovative life sciences companies like Sitryx are core to The Oxford Science Park, and we are delighted to see it expand to the Bellhouse Building. It's always exciting to see companies develop on site and we look forward to supporting Sitryx through its next phase of growth.'
Dr Neil Weir, CEO of Sitryx, said, 'This is an exciting time for us as we scale-up into excellent new premises in the Bellhouse Building, which will house teams working on multiple Lilly and Sitryx projects. We are delighted that this transition into new facilities has gone smoothly, according to timelines, particularly in the current climate.'
About Sitryx
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immunoinflammation. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism; Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak. Together they have published more than 1,000 papers in the field, making multiple key breakthroughs in our understanding of how critical energetic status is to the behavior of immune cells and in the broader field of immunology. In 2018, Sitryx raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020 Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the company. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK. For more information, please visit www.sitryx.com.
About The Oxford Science Park
The Oxford Science Park is owned and managed by Magdalen College, Oxford. Created in 1991, the Park upholds the College's heritage and provides one of the most influential science & technology environments in the UK. There is approaching 750,000 square feet of workspace accommodation across the Park, which is now home to 2,700 people and more than 130 businesses. These range from start-ups based in the Magdalen Centre innovation hub to major international companies and include Blue Earth Diagnostics, MiroBio, OrganOx, OxSonics Therapeutics, Oxford Nanopore Technologies, OXGENE, ProImmune, Oxford Sciences Innovation, Evox Therapeutics, Vaccitech, Exscientia, Sensyne Health and Intuitive Surgical.
In addition to being a key property investment, the Park is at the heart of Magdalen College's strategy to support discovery, innovation and entrepreneurship. It will continue to develop The Oxford Science Park as a longterm strategic asset, with ambitious plans to create an additional 500,000+ sq ft of office and laboratory space on the remaining 12 acres of land over the next 3-5 years. This additional capacity will support the growth of businesses already based on the Park, providing flexible workspace accommodation, and enabling new companies to enjoy the Park's exceptional environment and collegiate and collaborative ethos. The Oxford Science Park is located approximately four miles south-east of Oxford city centre, just off the City's southern ring road. It has easy access to the M40 and A34, as well as to Heathrow Airport and mainline train services. For further information, please visit: www.oxfordsp.com or follow us on twitter @OxfordSciencePK